Where I see patients (3)
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis.
Double trouble for Langerhans cell histiocytosis.
Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients.
Journal of pediatric hematology/oncology
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
DFS is defined as the time from the date of tisagenlecleucel infusion to the date of the first documented morphological relapse, occurrence of secondary malignancy or death due to any cause.
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemo...
The incidence of dose limiting toxicity (DLT) will be measured at different dose levels.
Epigenetic Reprogramming in Relapse/Refractory AML
The incidence of dose limiting toxicity (DLT) will be measured. The maximum tolerated dose will be the highest study dose at which 1 or fewer of six patients experience DLT during cycle 1 of therapy
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed...
MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity (DLT), will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4...
Smell the roses